{Reference Type}: Journal Article
{Title}: Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study.
{Author}: Teresita de Jesús CL;Edgar PB;Carlos Ruben NC;Marla TR;Juan Carlos RA;Raúl Adrián CF;Andrea GR;
{Journal}: Open Forum Infect Dis
{Volume}: 11
{Issue}: 8
{Year}: 2024 Aug
{Factor}: 4.423
{DOI}: 10.1093/ofid/ofae436
{Abstract}: We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.